The clinically organ-confined adenocarcinoma of the prostate

1. Front Matter

   Pages I-VIII

   PDF

2. Introduction and Overview

   • Hans-Peter Schmid

   Pages 1-13

3. Natural History

   • Hans-Peter Schmid

   Pages 14-33

4. Selection Criteria for Radical Prostatectomy

   • Hans-Peter Schmid

   Pages 34-41

5. Prognostic Factors Based on Long-term Follow-up

   • Hans-Peter Schmid

   Pages 42-63

6. References

   • Hans-Peter Schmid

   Pages 64-72

7. Summary

   • Hans-Peter Schmid

   Pages 73-73

8. Acknowledgments

   • Hans-Peter Schmid

   Pages 74-74

Dr. Hans-Peter Schmid has addressed in this monograph the basic dilemmas surrounding prostate cancer. These dilemmas include the 40 % histologic incidence of invasive cancer in men in comparison to a 3 % death rate, the extraordinary slow doubling time of four to five years for untreated early clinical stages (T1 and T2 cancers), the limited life span of even healthy men over 70 years of age, and the national and international debates of how to treat this cancer. It is important, however, to recognize that despite these uncertainties, prostate cancer is probably the most predictive of all human solid tumors. Dr. Schmid has addressed the basis for much of this predictability in this monograph. The level of serum PSA and its rate of increase in the untreated patient with a prostate size of less than 50 grams is undoub­ tedly the most useful of all measurements in predicting volume and grade of the cancer, but it is closely followed by assessment of the extent and percent of grade 4 and 5 cancer in six systematic, spatially separated biopsies. Estimating the amount of suspected cancer on digital rectal examination by assigning a clinical stage is useful, but far less quantitative than PSA and systematic biopsies. The Basel series in this monograph adds strong support to these basic concepts. April 1994 ThomasA. Stamey, M. D. Professor and Chairman Department of Urology Stanford University School of Medicine Stanford, California, USA v Contents Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V I. 1 Introduction and overview . . . . . . . . . . . . . . . . . . . . . . . . . . .

• Grading
• Staging
• cancer
• carcinoma
• prostate cancer
• prostatectomy
• tumor
• tumor progression

• Urologische Klinik, Universität Basel, Basel, Schweiz

  Hans-Peter Schmid

Policies and ethics